We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




High Levels of Vascular Endothelial Growth Factor Mark Noncancerous Pancreatic Cysts

By LabMedica International staff writers
Posted on 27 Feb 2014
A new noninvasive diagnostic test can differentiate benign pancreatic cysts from those that have the potential to progress to invasive pancreatic adenocarcinoma (pancreatic cancer).

Serous cystic neoplasms (SCN) have no malignant potential, but can mimic mucinous pancreatic cysts, which have the potential to progress to invasive pancreatic adenocarcinoma, on imaging. More...
The inability of medical imaging to readily differentiate between these two classes of cysts can result in patients having to go through extensive follow-up medical visits, invasive biopsies, and unnecessary surgery to determine the true nature of their pancreatic cyst.

Investigators at the Indiana University School of Medicine (Indianapolis, USA) hypothesized that vascular endothelial growth factor (VEGF)-A levels in pancreatic fluid might correlate with pathologic diagnosis of the pancreatic cyst. They used an ELISA assay to determine VEGF-A levels in pancreatic cyst fluid taken from 87 patients with suspicious pancreatic growths including pseudocysts, SCN, mucinous cystic neoplasm, low/moderate grade intraductal papillary mucinous neoplasm, high-grade/invasive intraductal papillary mucinous neoplasm, and pancreatic ductal adenocarcinoma.

Analysis of the data revealed that VEGF-A was significantly upregulated in SCN cyst fluid compared with all other diagnoses, and that VEGF-A had 100% sensitivity and 97% specificity as an SCN biomarker.

Senior author Dr. C. Max Schmidt, professor of surgery, biochemistry, and molecular biology at the Indiana University School of Medicine, said, "This is the first cyst fluid protein biomarker that can differentiate serous cystic neoplasms, a benign type of cystic lesion, from all other cancerous or precancerous cystic lesions without surgery."

"Only 15% of pancreatic cancer patients will benefit from surgery, and of those, only about 20% will survive five years," said Dr. Schmidt. "Many of my patients when initially told they have pancreatic cysts are very fearful and ask for surgical removal of the cyst or the entire pancreas before they even learn their options. Now, physicians will have an outpatient procedure to offer that can take some of the guesswork out of the equation.”

The study was published in December 24, 2013, online edition of the Journal of the American College of Surgeons.

Related Links:

Indiana University School of Medicine



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Gold Member
Pre- Eclampsia Control
Acusera Pre-Eclampsia Control
Clinical Informatics Platform
CLARION™
CMV CLIA Diagnostic
CLIA CMV IgA Screen Group
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: New findings demonstrate that anti-Müllerian hormone (AMH) may help identify which breast cancer patients are most likely to benefit from chemotherapy plus endocrine therapy (Image Credit: Shutterstock)

AMH Test Helps Predict Adjuvant Chemotherapy Benefit in Premenopausal Breast Cancer

Hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) breast cancer can present a difficult treatment decision in premenopausal patients with low recurrence scores.... Read more

Molecular Diagnostics

view channel
Image Credit: iStock

Sequencing-Based Newborn Screening Identifies Pediatric Cancer Risk at Birth

Newborn screening in the United States relies on heel-stick blood spots to identify rare, treatable disorders through biochemical testing, but these programs generally do not assess inherited cancer risk... Read more

Microbiology

view channel
Image: The QIAstat-Dx BCID GPF Plus AMR Panel is the first QIAstat-Dx panel for bloodstream infections to receive FDA clearance (Photo courtesy of Qiagen)

FDA Clears One-Hour Panel for Bloodstream Infection and AMR Detection

Bloodstream infections can rapidly progress to sepsis, a life-threatening condition affecting an estimated 1.7 million adults in the U.S. each year. Rapid identification of pathogens and antimicrobial... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.